• Adam Manhi (chair)

• Emma Salib (programme manager)

• Jennifer McCaffery (lay)

• Kaeden Bunting (lay)

• Thomas Smith (patient)

• Trishna Bharadia (patient)

• Shira Peleg Hasson (clinical)

No conflicts declared by panel

Approved

• Broad agreement the proposal, though complex, is well set out with clear goals for accessing real-world data.

• Clear alignment between teams requiring access, use cases, target outputs and proposed activities. Good examples of target outputs (e.g. ESMO conference).

• Well written lay summary - good overview of company, the drug, evidence to date and future aspirations.

• Section on planned activities is very clear, providing excellent rationale behind the data analysis and the need to identify real world survival rates.

• The panel raised several comments on other aspects of the application including:
  
  

  • Capturing additional details in the lay summary (e.g. % of population with metastatic colorectal cancer; survival rates; existing therapies).

  • Elaborating further on how findings will be disseminated to patients.